drugset / Trial / NCT04284488
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.
Timeline
- Start
- 2020-04-10
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-1387 | Small molecule | 20 mg | Intravenous |
| Subject | APG-1387 | Small molecule | 30 mg | Intravenous |
| Subject | APG-1387 | Small molecule | 45 mg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |